Physician profile
Christopher T Yingling
NPI 1912153503
$6,311.18
in general payments reported to CMS, 2019-2025
33 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $191 · 2021: $368 · 2022: $1,031 · 2023: $1,551 · 2024: $1,348 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,839 · Gift: $203 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.51 |
| Gift | $202.50 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,026.09 | 2019-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $813.36 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $705.83 | 2020-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $532.72 | 2023-2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $373.03 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $359.19 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $332.53 | 2019-2024 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $259.80 | 2021-2025 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $239.00 | 2022-2025 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $209.68 | 2023-2025 | Jelmyto |
| Intuitive Surgical, INC. | $202.50 | 2023 | Da Vinci Surgical System |
| Endo USA, INC. | $197.06 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $142.11 | 2024-2025 | Adstiladrin |
| Procept Biorobotics Corporation | $128.14 | 2022-2025 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $90.88 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $82.45 | 2022 | |
| Myovant Sciences INC. | $77.80 | 2022 | |
| Dendreon Pharmaceuticals LLC | $68.43 | 2019 | |
| Olympus America INC. | $64.35 | 2019-2025 | Itind System |
| Karl Storz Endoscopy-America | $58.39 | 2022-2023 | N.A. |
| Allergan, INC. | $49.83 | 2019-2020 | |
| Tolmar, INC. | $45.61 | 2024-2025 | Jatenzo, Eligard |
| Tolmar Pharmaceuticals, INC. | $44.35 | 2021-2022 | |
| Astellas Pharma Global Development | $42.76 | 2022 | |
| Axonics, INC. | $36.45 | 2023 | Bulkamid, Axonics |
| Boston Scientific Corporation | $25.12 | 2019 | |
| 180 Medical, INC. | $19.46 | 2020 | |
| Photocure INC | $18.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.08 | 2021 | |
| Convatec INC. | $16.55 | 2024 | |
| Antares Pharma, INC. | $15.18 | 2022 | |
| Neotract INC. | $11.89 | 2019 | |
| Travere Therapeutics, INC. | $5.56 | 2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yingling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.